Cargando…

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

Since 1997, highly pathogenic avian influenza viruses of the H5N1 subtype have been transmitted from avian hosts to humans. The severity of H5N1 infection in humans, as well as the sporadic nature of H5N1 outbreaks, both geographically and temporally, make generation of an effective vaccine a global...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Hoeven, Neal, Fox, Christopher B., Granger, Brian, Evers, Tara, Joshi, Sharvari W., Nana, Ghislain I., Evans, Sarah C., Lin, Susan, Liang, Hong, Liang, Li, Nakajima, Rie, Felgner, Philip L., Bowen, Richard A., Marlenee, Nicole, Hartwig, Airn, Baldwin, Susan L., Coler, Rhea N., Tomai, Mark, Elvecrog, James, Reed, Steven G., Carter, Darrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399443/ https://www.ncbi.nlm.nih.gov/pubmed/28429728 http://dx.doi.org/10.1038/srep46426

Ejemplares similares

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach
por: Fox, Christopher B., et al.
Publicado: (2016)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
por: Baldwin, Susan L., et al.
Publicado: (2018)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
por: Baldwin, Susan L., et al.
Publicado: (2022)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

SARS-CoV-2 infection and immune responses
por: Harne, Rakhi, et al.
Publicado: (2023)

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
por: Larsen, Sasha E., et al.
Publicado: (2018)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Mycobacterium abscessus: It’s Complex
por: Abdelaal, Hazem F. M., et al.
Publicado: (2022)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
por: Coler, Rhea N., et al.
Publicado: (2010)

Development of a Hamster Model for Chikungunya Virus Infection and Pathogenesis
por: Bosco-Lauth, Angela M., et al.
Publicado: (2015)

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites
por: Hofmeyer, Kimberly A., et al.
Publicado: (2016)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
por: Fox, Christopher B, et al.
Publicado: (2014)

Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses
por: Fratzke, Alycia P., et al.
Publicado: (2021)

Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas
por: Adney, Danielle R., et al.
Publicado: (2016)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

Biodetection of a specific odor signature in mallard feces associated with infection by low pathogenic avian influenza A virus
por: Golden, Glen J., et al.
Publicado: (2021)

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
por: Larsen, Sasha E., et al.
Publicado: (2023)

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
por: Mullins, Stefanie R., et al.
Publicado: (2019)

The adjuvant GLA-AF enhances human intradermal vaccine responses
por: Carter, Darrick, et al.
Publicado: (2018)

Inoculation of Goats, Sheep, and Horses with MERS-CoV Does Not Result in Productive Viral Shedding
por: Adney, Danielle R., et al.
Publicado: (2016)

Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
por: Berube, Bryan J., et al.
Publicado: (2022)

Oral Administration of Universal Bacterium-Vectored Nucleocapsid-Expressing COVID-19 Vaccine is Efficacious in Hamsters
por: Jia, Qingmei, et al.
Publicado: (2023)

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
por: Abhyankar, Mayuresh M., et al.
Publicado: (2018)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration
por: Maloney, Sara E., et al.
Publicado: (2023)

Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection
por: Erasmus, Jesse H., et al.
Publicado: (2020)

Editorial: Beyond Th1: Novel concepts in tuberculosis vaccine immunology
por: Dijkman, Karin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6fcmis4402urtm7n6gjfiap6bq